The Readout Loud

News & Politics Podcasts

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Episodes

417: Hospitals' next lucrative bet — longevity clinics

416: NIH funding uncertainty thwarts U.S. researchers

415: Mistrust in science and a juicy gene-editing lawsuit

The FDA's Overton era, and dispatches from Shanghai

Definium's new psychedelics data, and a reprieve for international scientists

Why two promising heart drugs flopped and what's next

411: Capricor's data clash and a fugitive in the C-suite

410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing

409: Predicting biotech clinical trials & a new Alzheimer's drug controversy

408: Whistleblower takes on health insurance and FDA commissioner candidates

407: The mysterious case of Eli Lilly's obesity drug

406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises

405: An obesity drug deep-dive, and peptides move mainstream

404: What RevMed's pancreatic cancer drug meant for one patient

403: Biotech exec Jeremy Levin on the industry's strategic turning point

402: Guarding biotech from China and big bets in longevity

401: Makary’s departure and Cassidy’s tenuous Senate seat

400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles

399: Hair-raising trial results, and Servier’s M&A wishlist

398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts